Kelsey Murphy, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 339 Flanders Rd, East Lyme, CT 06333 Phone: 860-739-6437 Fax: 860-739-2901 |
Mrs. Julie Lynn Summers, MS, CCC-SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 9 Irvingdell Pl, East Lyme, CT 06333 Phone: 860-460-3475 Fax: 860-650-0010 |
On Point Speech Therapy, Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 9 Irvingdell Pl, East Lyme, CT 06333 Phone: 860-460-3475 Fax: 860-650-0010 |
Guiding Light Speech Therapy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 310r Flanders Rd Pmb 2012, East Lyme, CT 06333 Phone: 802-688-4635 |
News Archive
Metastasis of tumors to level IIb lymph nodes is rare in patients with laryngeal squamous cell carcinoma (LSCC); this area can be ignored during selective neck dissection (SND) to avoid damaging the spinal accessory nerve (SAN), making this surgery more conservative and minimizing SAN morbidity, according to the March 2012 issue of Otolaryngology-Head and Neck Surgery.
Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.
The first two COVID-19 vaccines authorized for emergency use by the Food and Drug Administration (FDA) employed a technology that had never before been used in FDA-approved vaccines.
Research published this week in Scientific Reports uses computer image and statistical shape analysis to shed light on which parts of the face are most likely to be inherited.
Growth in global prescription drug spending will slow to the lowest rate in decades as low-cost generic drugs continue replacing former blockbusters in the U.S. and Europe, where governments face new pressure to reduce health care spending, according to a new forecast. The projection from data firm IMS Health shows the global prescription drug market growing by 3 to 6 percent over the next four years to $1.2 trillion by 2017.
› Verified 2 days ago